Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
somebody got nervous lol
Nice! By the way I have been hanging out here for the last few weeks. I wish this board was not so quiet.
https://www.reddit.com/r/Silverbugs/
I am heavy on some cheap January SLV calls. It silver starts to move I will be a happy camper.
Silver infused Gorilla Glass hits the market
Antimicrobial Corning Gorilla Glass helps protect the ZTE AXON's 5.5-inch touchscreen from damage as well as odor and stain causing bacteria
CORNING, N.Y., July 21, 2015 - Corning Incorporated GLW, +0.88% today announced that ZTE Corporation has chosen Antimicrobial Corning(R) Gorilla(R) Glass for its newest flagship smartphone in China, the ZTE AXON.
"With the rise of touch technology and our constant interaction with people and public surfaces, the microbes on our smartphones are not our own," said Dr. Joydeep Lahiri, division vice president and program director, Specialty Surfaces, Corning Incorporated. "We developed Antimicrobial Corning Gorilla Glass to address this concern and are excited to see this technology enter the consumer electronics space with the launch of the ZTE AXON."
Antimicrobial Corning Gorilla Glass is the first EPA-registered antimicrobial cover glass. It combines the renowned benefits of Corning Gorilla Glass technology, including durability, scratch resistance and toughness, with a built-in antimicrobial property to last the lifetime of the display cover glass.
"We are delighted to work with Corning to offer the first smartphone with Antimicrobial Corning Gorilla Glass," said Dr. Ji Zhongwei, chief technology officer of ZTE Mobile Devices and vice president of ZTE Corporation. "The AXON phone is our flagship device and incorporates the latest innovations in smartphone hardware and software in a stylish package that we believe will have outstanding customer appeal."
Corning Gorilla Glass is the world leader in damage-resistant cover glass. Since its launch in 2007, Corning Gorilla Glass has been featured in nearly 4 billion devices worldwide on more than 1,550 product models across 40 major brands. Antimicrobial Corning Gorilla Glass is the same product with added antimicrobial properties. For more information on Corning Gorilla Glass, visit the website.
Disclaimer
Antimicrobial Corning(R) Gorilla(R) Glass is formulated with antimicrobial properties to help protect touch surfaces from stain and odor-causing bacteria. Corning makes no direct or implied claims to protecting users or providing other health benefits.
Silver infused Gorilla Glass hits the market
Antimicrobial Corning Gorilla Glass helps protect the ZTE AXON's 5.5-inch touchscreen from damage as well as odor and stain causing bacteria
CORNING, N.Y., July 21, 2015 - Corning Incorporated GLW, +0.88% today announced that ZTE Corporation has chosen Antimicrobial Corning(R) Gorilla(R) Glass for its newest flagship smartphone in China, the ZTE AXON.
"With the rise of touch technology and our constant interaction with people and public surfaces, the microbes on our smartphones are not our own," said Dr. Joydeep Lahiri, division vice president and program director, Specialty Surfaces, Corning Incorporated. "We developed Antimicrobial Corning Gorilla Glass to address this concern and are excited to see this technology enter the consumer electronics space with the launch of the ZTE AXON."
Antimicrobial Corning Gorilla Glass is the first EPA-registered antimicrobial cover glass. It combines the renowned benefits of Corning Gorilla Glass technology, including durability, scratch resistance and toughness, with a built-in antimicrobial property to last the lifetime of the display cover glass.
"We are delighted to work with Corning to offer the first smartphone with Antimicrobial Corning Gorilla Glass," said Dr. Ji Zhongwei, chief technology officer of ZTE Mobile Devices and vice president of ZTE Corporation. "The AXON phone is our flagship device and incorporates the latest innovations in smartphone hardware and software in a stylish package that we believe will have outstanding customer appeal."
Corning Gorilla Glass is the world leader in damage-resistant cover glass. Since its launch in 2007, Corning Gorilla Glass has been featured in nearly 4 billion devices worldwide on more than 1,550 product models across 40 major brands. Antimicrobial Corning Gorilla Glass is the same product with added antimicrobial properties. For more information on Corning Gorilla Glass, visit the website.
Disclaimer
Antimicrobial Corning(R) Gorilla(R) Glass is formulated with antimicrobial properties to help protect touch surfaces from stain and odor-causing bacteria. Corning makes no direct or implied claims to protecting users or providing other health benefits.
If ISIS is allowed to spread they will eventually try to hit the US and Israel.
http://time.com/3964197/isis-chemical-weapons/
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
MISSION VIEJO, CA--(Marketwired - May 28, 2015) - Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today that David C. Cavalier, Chairman and Chief Financial Officer, will present at the LD Micro Invitational Conference on Tuesday, June 2nd, 2015 at 11:30 AM PDT (2:30 PM EDT) at the Luxe Sunset Boulevard Hotel in Los Angeles. Mr. Cavalier will provide an overview of Aeolus' development programs with a focus on the Company's progress under its contract with the Biomedical Advanced Research and Development Authority ("BARDA"). The BARDA contract, worth up to $118.4 million, funds all development costs for the Company's lead compound, AEOL 10150, as a treatment for the pulmonary effects of acute radiation exposure ("Lung-ARS") following a nuclear event.
"We are honored to have Aeolus Pharmaceuticals present at the conference," stated Chris Lahiji, President of LD Micro.
A webcast of the presentation will be available live on the Company's website at www.aolsrx.com. The presentation will also be archived for viewing after the conference
http://finance.yahoo.com/news/aeolus-pharmateucticals-present-ld-micro-113000740.html
lol good idea!
Oh yeah, I keep my metal in a safety deposit box. I know a lot of stackers would disagree with that being that banks might lock the doors in a crises.
Hey I got my order in from Apmex today, and decided to do my first unboxing video. Enjoy!
Yeah I think in the next month we will be in that range. I don't really know, but I am not selling. I unloaded half my position over the last month just because I had too much. I had gotten to the point that I was not able to rest comfortably with the position I had. It was just too large. I sold in small chunks over a period of a month.
I plan on holding these shares well past .50. We will see. I honestly believe this could be a $5 stock in the next couple years.
Yeah man we just never know when that time will come. All the silver in the world won't mean a thing after we are gone. I like the way Frances Chan lays things out:
Peter Schiff: U.S. Economy Teetering on the Brink of Recession
Interesting article:
http://silverseek.com/article/silver-price-projections-2020-14425
... I offer 3 scenarios based on various combinations of the above macro-economic conditions.
SPECULATION REGARDING SILVER PRICES IN 2020:
MORE OF THE SAME SCENARIO: (I find this unlikely but the media likes it.)
[#] US population adjusted national debt increases at 6.7%. (30 year average)
[#] The S&P oscillates around 2,000 as the economy weakens.
[#] No nuclear war, no financial meltdown, the usual politics, a “Demo-Publician” is elected in 2016, and no “black swans” swoop in to destabilize our financial world.
[#] Silver is priced about $35 to $50, based on the exponentially increasing SUM.
CHICKENS COME HOME TO ROOST SCENARIO:
[#] US population adjusted national debt increases more rapidly at about 7.5% per year until 2020. (Wars are expensive!)
[#] The S&P weakens to average (guessing) 1,200 to 2,000.
[#] The US dollar weakens compared to many other currencies and substantially against gold.
[#] By 2020 many financial and paper assets are recognized as dangerous and gold and silver have been revalued far higher.
[#] The SUM rises to the high end of its 30 year exponential range, and silver prices average about $80 to $120. Given silver’s volatility, history of manipulation, and small market, silver could spike higher toward $200.
HYPERINFLATIONARY SCENARIO for 2020:
[#] Debt escalates out of control to unimaginable numbers. Governments find someone else to blame.
[#] The S&P 500 Index goes parabolic.
[#] Financial TV commentators are practically breathless as they discuss the huge increases in the S&P and ignore the rampant inflation, unemployed workers, human misery, and social distress.
[#] Social and economic conditions are deadly and exceedingly difficult.
[#] Income equality in the western world worsens and riots become more common.
[#] Silver prices go parabolic and reach currently unthinkable numbers.
CONCLUSIONS REGARDING ALL SCENARIOS:
History and current actions justify the expectation that governments and central banks will increase debt, devalue fiat currencies, and thereby force silver and gold prices much higher.
Convert digital dollars, yen, pounds, and euros into silver and gold while you can. Current “on sale” prices will not last much longer.
For sure $18 will fall this week I think. I ordered one of these on May 5th. It is supposed to ship today, can't wait for it to get here.
http://www.apmex.com/product/84703/100-oz-silver-bar-republic-metals-corporation-rmc
So if you want a lotto silver play then load up on $25 SLV calls for January 2016. It is a real gamble, but I picked up 50 calls @ .14 a couple days ago. Just think the $750 you spend on the 50 calls could be worth 25k if slv goes to $30 over the next six month.
Again it is a total lotto play and very risky. On the other hand if silver goes back to a 16:1 ratio over the next six months you could be up $225k. Really the trade is a really bad idea, but I like playing these lotto plays here and there.
I buy all my silver via apmex. I've tried others and apmex is the best. I even use them for my metal IRAs. By the way Apmex is running a 4 hours sale right now on their Philharmonics right now for $1.79 over spot. I am so tempted to pick some up.
More on JP Morgan Silver Purchases:
http://www.goldcore.com/us/gold-blog/ted-butler-the-biggest-silver-haul-in-history/
Pro-Life have you seen this:
If you look at the comex website it looks like JP Morgan is buying a whole lot of silver. Just yesterday they bought 235k oz.
(http://www.cmegroup.com/delivery_reports/MetalsIssuesAndStopsReport.pdf)
That brings them up to 6.2 million oz for May (http://www.cmegroup.com/delivery_reports/MetalsIssuesAndStopsYTDReport.pdf) See page 14.
By the way in the pdf each contract represents 5000 oz. So the 809 contracts times 5000 oz is just over 4 million oz. Also in the report the I or Issued is a sell and the Stopped or S is where they took ownership of the silver.
(http://www.cmegroup.com/delivery_reports/MetalsIssuesAndStopsYTDReport.pdf)
Right or wrong, i just purchased some more silver for my IRA. I've been waiting over a year now for it to come down. I really wanted to purchase at $15, but it just kept bouncing off that level.
Oh yeah the world silver report comes out tomorrow: https://www.silverinstitute.org/site/
That 8-k is huge! Sounds like a country who fears Iranian nukes are going to take preventative measures.
Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
MISSION VIEJO, CA--(Marketwired - May 04, 2015) - Aeolus Pharmaceuticals, Inc. (AOLS)
FINDINGS REPORTED BY DR. THOMAS MACVITTIE OF THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE WILL BE INCLUDED IN A PRE-EMERGENCY USE AUTHORIZATION SUBMISSION TO THE FDA
ADMINISTRATION OF AEOL 10150 MITIGATED SECONDARY MEASURES OF LUNG INJURY
DIMINISHED RADIOGRAPHIC EVIDENCE OF PNEUMONITIS AND FIBROSIS IN AEOL 10150-TREATED GROUP
ADVANCED IMAGING INDICATES BIOMARKERS FOR LUNG DAMAGE IN IRRADIATED LUNGS NOT PRESENT IN GROUP TREATED WITH AEOL 10150
Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with significant funding from the US Government, announced complete results from a successful study in non-human primates (NHPs) demonstrating that 60 days of treatment with AEOL 10150 improved survival from 25 percent to 50 percent -- doubling survival at 180 days after radiation exposure to the lungs. Top line survival results from the study were originally reported by the Company in September 2014. The complete results include clinical and radiographic measures of secondary parameters of lung injury as well as imaging of potential biomarkers for lung damage.
"This study, conducted in a very severe model of lung injury, provided critical evidence for a significant survival-effect as well as helping to define the best treatment protocol for administration of AEOL 10150. The final assessment of key secondary parameters indicative of both clinical and radiographic evidence of lung injury showed an overwhelming positive effect of treatment with AEOL 10150," stated Thomas MacVittie, PhD, Professor, Department of Radiation Oncology, University of Maryland School of Medicine.
The study found that administration of AEOL 10150 for 60 days beginning 24 hours after exposure to 10.74 Gy of radiation:
Increased overall survival from 25% in the untreated control group to 50%
Increased mean and median overall survival time
Increased mean and median survival time in subjects that did not survive to 180 days
Increased time to onset of increased respiratory rate, a clinical measure of lung injury
Decreased mortality in subjects with elevated respiratory rate
Decreased wet lung weight in all animals, suggesting less parenchymal damage and edema
Increased Sp02, a measure of compensated lung function
Diminished radiographic evidence of pneumonitis and fibrosis during the later stages of the study (days 90 -180)
In addition, a new approach to investigating lipids, metabolites and proteins in pathophysiological process, matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was employed in the study to measure potential biomarkers for lung injury in tissue samples from study subject. Analysis using MALDI-MSI showed that the molecular profile for the naïve (un-irradiated) lung is statistically distinct from irradiated lung and treatment with AEOL 10150 shifts the molecular profile back towards the naïve lung. Two prospective biomarkers found in irradiated, damaged lung tissue were not detectable in either naïve or AEOL 10150-treated samples.
The study was conducted by researchers at the University of Maryland School of Medicine (UM SOM) led by Thomas MacVittie, PhD, Professor, Division of Translational Radiation Sciences, UM SOM Department of Radiation Oncology. The research builds on 40 years of work that Dr. MacVittie and his team have conducted in the field of radiation research during which they have helped to define the field of radiation research and have developed efficacy models for radiation damage that focus on the hematopoietic, gastrointestinal and lung sub-syndromes of Acute Radiation Syndrome (ARS) and the Delayed Effects of Acute Radiation Exposure (DEARE). The models developed by his team were published in two issues of the Health Physics Journal, October 2012 and January 2014 and have been presented to the FDA. The FDA has concurred with the hematopoietic and lung models developed by the MacVittie Lab. His team, led by Ann Farese, also conducted the GLP-compliant pivotal efficacy studies that led to FDA approval on March 30, 2015 of Neupogen® (filgrastim) as the first drug or medical countermeasure approved under the FDA "Animal Rule" to treat adult and pediatric patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome, or H-ARS).
"The results from this comprehensive study further confirm the efficacy of AEOL 10150 in mitigating the lung damage from radiation exposure," stated John L. McManus, President and Chief Executive Officer of Aeolus Pharmaceuticals, Inc. "We are pleased to see that the secondary endpoints support the significant survival improvement reported when AEOL 10150 is given for 60 days after extremely high levels of radiation to the lungs. AEOL 10150 has significantly improved survival in more than a dozen studies of lethal chemical and radiological exposure to the lungs, and the results of this study also further support its anti-fibrotic properties. The biomarker and lipid data from the imaging work done in this study is critical as it helps further the understanding of the damage radiation exposure does to the lungs and how AEOL 10150 mitigates that damage. We remain grateful to our colleagues at the University of Maryland for their excellent research and to the Biomedical Advanced Research and Development Authority for their support of the AEOL 10150 Lung ARS development program and to the National Institutes of Health, National Institute of Allergy and Infectious Diseases for their funding of the MALDI-MSI Imaging."
About AEOL 10150
AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation and subsequent tissue damage resulting from radiation exposure. The Company believes that AEOL 10150 could have a profound beneficial impact on people who are exposed to high doses of radiation.
AEOL 10150 has already performed well in animal safety studies, was well tolerated in two human clinical trials and has demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Aeolus has received "Orphan Drug" designation for the use of AEOL 10150 in treating lung ARS and Idiopathic Pulmonary Fibrosis and has filed an IND to allow for human safety testing of the compound in healthy volunteers. AEOL 10150 is also currently in development for use in Idiopathic Pulmonary Fibrosis and as both a therapeutic and prophylactic drug in cancer patients.
About Aeolus Pharmaceuticals
nice move! 50s coming? I think so
Nice close with good dollar volume today. Looking for us to move into those 40's soon.
This is getting really thin, i believe we are really close to the next leg up.
Those .50s are coming again for sure. I would say in the next couple months. The company has never had this amount of news, it is just a matter of time until everything falls in place. It is a waiting game at this point.
Yahoo has a $1.25 Estimate 1 Year Price Target
What do y'all think of that? Too high? Too low?
Looks like we have some good buys in the .30s over the last few weeks. Should be a nice foundation to build on.
Notice of Allowance From Israeli Patent Office
More progress being made. Thinks look to be coming together nicely.
http://finance.yahoo.com/news/aeolus-receives-notice-allowance-israeli-120000159.html
CFO David C. Cavalier speaking about Aeolus.
I know, hating it.
2015 Catalysts and Milestones
http://content.stockpr.com/aolsrx/media/04530e34d78653e8343cea2f2058258e.pdf
Response to FDA Clinical Hold Q1 2015
Full Data from NHP Study Q1 2015
Orphan Drug Filing - Lung Fibrosis Q1 2015
File IND for Radiation Oncology Q1 2015
Fast Track Filing for Lung-ARS Q1 2015
Lung-ARS Duration of Treatment and Treatment Window Studies Q1 2015
Meet with FDA Respiratory Division to Discuss IPF IND Q1 2015
Chlorine Gas Data Q1 2015
Initiate Phase I in Oncology Q2 2015
Well it has been about a year and this one finally got great news today:
AOLS Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
"Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits."
Keep this one on your list. They have a phase one cancer trial coming up for the effects of radiation on the lungs. Lots of good stuff ahead here.
http://finance.yahoo.com/news/aeolus-receives-orphan-drug-designation-154629158.html
AOLS Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
"Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits."
Keep this one on your list. They have a phase one cancer trial coming up for the effects of radiation on the lungs. Lots of good stuff ahead here.
http://finance.yahoo.com/news/aeolus-receives-orphan-drug-designation-154629158.html
News? Great move here, I think we could be back in the .50s before we know it.
Now this is big news IMO
http://ih.advfn.com/p.php?pid=nmona&article=65875035
Lift off coming?
these large buys keep happening for weeks now. Today another 30k+ shares purchased after hours today. Someone is loading this thing.
For sure once we can get past the resistance at $2.93, that gap will start to close much faster.
Nice move today.